Literature DB >> 17347281

Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.

Marta Kalousová1, Marie Jáchymová, Oto Mestek, Magdaléna Hodková, Markéta Kazderová, Vladimír Tesar, Tomás Zima.   

Abstract

BACKGROUND: The receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of vascular and inflammatory diseases. The pathological effects mediated via RAGE are physiologically inhibited by soluble RAGE (sRAGE). Our aim was to study sRAGE and RAGE gene polymorphisms in haemodialysis (HD) patients.
METHODS: A total of 261 stable HD patients were enrolled in the study and prospectively followed up for 30 months. At the begining of the study, sRAGE inflammatory and nutritional parameters were determined. RAGE polymorphisms were determined in a subgroup of 214 HD patients. A group of 100 healthy controls was used for comparison.
RESULTS: In HD patients, sRAGE is elevated in comparison with healthy controls (3427+/-1508 vs 1758+/-637 pg/ml, P<0.001). It correlates negatively with residual diuresis (r=-0.193, P<0.05), with the acute phase reactants fibrinogen (r=-0.174, P<0.05) and orosomucoid (r=-0.135, P<0.05) and with the leucocyte count (r=-0.158, P<0.05). On the other hand, it is not related to the presence of diabetes mellitus, cardiovascular disease, nutritional status and mortality. The highest sRAGE levels are found in -429 CC and 2184 GG polymorphisms of the RAGE gene. The same results as for sRAGE were obtained for endogenous secretory RAGE (esRAGE), which correlated significantly with sRAGE (r=0.88, P<0.001).
CONCLUSION: We conclude that in HD patients, sRAGE is increased due to decreased renal function, which is a very strong determinant of sRAGE levels, and is inversely related to inflammation. The highest sRAGE levels are influenced genetically. In our study, sRAGE levels were not related to mortality of HD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347281     DOI: 10.1093/ndt/gfm050

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  23 in total

1.  Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer.

Authors:  Matúš Chocholatý; Marie Jáchymová; Marek Schmidt; Klára Havlová; Anna Křepelová; Tomáš Zima; Marko Babjuk; Marta Kalousová
Journal:  Tumour Biol       Date:  2014-11-19

2.  Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients.

Authors:  Mohamed M Nasrallah; Amal R El-Shehaby; Noha A Osman; Mona M Salem; Amr Nassef; Usama A A Sharaf El Din
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

3.  Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.

Authors:  M C Thomas; J Söderlund; M Lehto; V-P Mäkinen; J L Moran; M E Cooper; C Forsblom; P-H Groop
Journal:  Diabetologia       Date:  2011-05-24       Impact factor: 10.122

4.  Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.

Authors:  Makiko Katagiri; Jun Shoji; Satoshi Kato; Shigehiko Kitano; Yasuko Uchigata
Journal:  Int Ophthalmol       Date:  2016-11-09       Impact factor: 2.031

5.  Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.

Authors:  Ayumu Nakashima; Juan Jesús Carrero; Abdul Rashid Qureshi; Tetsu Miyamoto; Björn Anderstam; Peter Bárány; Olof Heimbürger; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 8.237

Review 6.  Dangers within: DAMP responses to damage and cell death in kidney disease.

Authors:  Diane L Rosin; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2011-02-18       Impact factor: 10.121

Review 7.  Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

8.  Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska; Monika Młot-Michalska
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

Review 9.  The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.

Authors:  Jyotiska Chaudhuri; Yasmin Bains; Sanjib Guha; Arnold Kahn; David Hall; Neelanjan Bose; Alejandro Gugliucci; Pankaj Kapahi
Journal:  Cell Metab       Date:  2018-09-04       Impact factor: 27.287

Review 10.  RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.